Participating Faculty

Supplements and Featured Publications, Discussing the COSTS of Asthma: Controlling Outcomes, Symptoms, and Treatment Strategies, Volume 11, Issue 11 Suppl

The American Journal of Managed Care

This supplement to includes information on controlling asthma outcomes, symptoms, and treatment strategies. It has been peer reviewed by an expert in the field.

Faculty

Principal Authors

Donald A. Bukstein, MDDirector, Allergy and Asthma Research

Assistant Clinical Professor

University of Wisconsin

Assistant Professor of Clinical Pediatrics

University of Southern California

Professor of Medicine

Tampa, Florida

Peter Smith, MD

Long Island College Hospital

SUNY Downstate Medical Center

Instructor in Medicine

Associate Physician

Boston, Massachusetts

Contributing Author

Frank L. Urbano, MD, FACP

Mount Laurel, New Jersey

Disclosure Statement

PRIME® Disclosure Statement

PRIME® holds the standard that its continuing medical education programs be free of commercial bias. The faculty have been asked to disclose any relationship they have with companies producing pharmaceuticals, medical equipment, etc, that might be germane to their contribution(s) to this CME/CE activity or any relationship they have with the commercial supporter of the program. These disclosures are not intended to suggest or condone bias but are elicited to provide participants with information that might be of potential importance in their evaluation of the program. The faculty has reported receiving something of value from a company whose product may be germane to the content of the program. Something of value refers to an equity position, vested interest, receipt of royalties, consultantship, funding by a research grant, honoraria received for educational services, or any other relationship to a company that provides sufficient reason for disclosure. The content of this CME activity may contain discussions of off-label uses of some of the agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

The American Journal of Managed Care

It is the policy of to have all faculty who participate in programs sponsored by pharmaceutical companies disclose any real or apparent conflicts of interest.

These participants disclose the following:

Consultant to/participated in physician

education programs/served on

asthma advisory boards for/and/or

has been a member of speakers'

bureaus for:

  • American College of Allergy, Asthma, and Immunology
  • American Lung Association
  • AstraZeneca
  • GlaxoSmithKline
  • Novartis
  • Schering-Plough

Grant/research support from:

  • Merck

Consultant to:

  • Genentech
  • Sanofi-Aventis

Speakers' bureau for:

  • Genentech
  • Novartis

Grant/research support from:

  • Genentech
  • Novartis

Consultant for:

  • Medpointe

Clinical investigator for:

  • GlaxoSmithKline
  • Novartis

Speaker

's bureau for and

major stockholder with:

  • AstraZeneca
  • GlaxoSmithKline
  • Novartis
  • Schering

Consultant for:

  • Genentech
  • Novartis

Speakers' bureau for:

  • GlaxoSmithKlein
  • Pfizer

Consultant to:

  • GlaxoSmithKline
  • Novartis/Genentech

Speakers' bureau for:

  • GlaxoSmithKline
  • Novartis-Genentech
  • Frank L. Urbano, MD, FACP Dr Urbano discloses that he is the medical director for PRIME®, the accredited provider of this CME activity.